References
- Peer D , KarpJM, HongS, FarokhzadOC, MargalitR, LangerR. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2 (12), 751–760 (2007).
- Petros RA , DesimoneJM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov.9 (8), 615–627 (2010).
- Farokhzad OC , LangerR. Impact of nanotechnology on drug delivery. ACS Nano3 (1), 16–20 (2009).
- Yoo JW , IrvineDJ, DischerDE, MitragotriS. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov.10 (7), 521–535 (2011).
- Macdiarmid JA , MugridgeNB, WeissJCet al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell11 (5), 431–445 (2007).
- Wu W , HsiaoSC, CarricoZM, FrancisMB. Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem. Int. Ed.48 (50), 9493–9497 (2009).
- Tong GJ , HsiaoSC, CarricoZM, FrancisMB. Viral Capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc.131 (31), 11174–11178 (2009).
- Alvarez-Erviti L , SeowYQ, YinHF, BettsC, LakhalS, WoodMJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol.29 (4), 341-U179 (2011).
- El Andaloussi S , MaegerI, BreakefieldXO, WoodMJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov.12 (5), 348–358 (2013).
- Gujrati V , KimS, KimSHet al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano8 (2), 1525–1537 (2014).
- Lee EY , ChoiDS, KimKP, GhoYS. Proteomics in Gram-negative bacterial outer membrane vesicles. Mass Spectrom. Rev.27 (6), 535–555 (2008).
- Kuehn MJ , KestyNC. Bacterial outer membrane vesicles and the host-pathogen interaction. Gene Dev.19 (22), 2645–2655 (2005).
- Kim JY , DoodyAM, ChenDJet al. Engineered bacterial outer membrane vesicles with enhanced functionality. J. Mol. Biol.380 (1), 51–66 (2008).
- Chen DJ , OsterriederN, MetzgerSMet al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl Acad. Sci. USA107 (7), 3099–3104 (2010).
- Hajjar AM , ErnstRK, TsaiJH, WilsonCB, MillerSI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol.3 (4), 354–359 (2002).
- Somerville JE , CassianoL, DarveauRP. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun.67 (12), 6583–6590 (1999).
- Baselga J , SwainSM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9 (7), 463–475 (2009).
- Orlova A , MagnussonM, ErikssonTLJet al. Tumor Imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res.66 (8), 4339–4348 (2006).
- Judge AD , RobbinsM, TavakoliIet al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest.119 (3), 661–673 (2009).